Episurf Medical receives CE mark for its fifth product, EpioscopyTM Damage Assessment Tool

EpioscopyTM is an intelligent, patient specific decision support tool, generated through the company’s proprietary uiFidelity platform. With this new addition, Episurf Medical expands its product portfolio to include a stand-alone digital service aimed at surgeons and patients.

This information was published, 2016-01-15 08:59 CET (GLOBE NEWSWIRE) —
 

EpioscopyTM is an advanced clinical assessment tool intended to provide the physician with decision support information in the form of 3D-vizualizations of the segmented patient knee, visual marking of chondral and osteochondral lesions in the femoral part of the knee and a written assessment of structural deviations on the tibia, patella, meniscus and ACL. In the event that Episurf Medical’s implant solutions are considered to be an appropriate treatment option, a visualization of the implant/guide is added to the 3D-image of the knee

“We see the EpioscopyTM Damage Assessment Tool as a non-invasive complement to arthroscopy to enhance clinical decision making, with the ambition to further develop this product into a viable diagnostic tool. It is the company’s intention to also offer the EpioscopyTM service directly to prospective patients who are seeking treatment options following previously unsuccessful cartilage repair procedures” says Rosemary Cunningham Thomas, CEO of Episurf Medical.

The global market for arthroscopic interventions is approximately 2 million per annum with a price range between USD 1000 – USD 2000. Given the consistent accuracy rate of Episurf Medical’s damage marking process, the EpioscopyTM tool aims to provide surgeons with a detailed patient specific assessment; the result being more cost effective care.

“Consistent customer feedback has helped the company understand the unique and significant value of our pre-surgical damage marking report as an intelligent planning guide which will be positioned to create new software as a service revenue streams“, says CEO Rosemary Cunningham Thomas. “It’s also the view of Episurf Medical’s Clinical Advisory Board that our pre-surgical assessment report offers a form of quality control that leads to appropriate procedure and patient selection, thereby improving clinical outcomes and patient satisfaction“.

Episurf Medical now has five patient specific products on the market which complement each other and help give people who suffer from joint pain a second chance to a live a normal and pain free life where previous treatments have failed.

“In the emerging field of early osteoarthritis, we believe a company that combines patient specific implants with sophisticated digital decision making tools is very attractive to surgeons, patients and investors. Advanced imaging techniques, combined with Episurf Medical’s core competency in assessing cartilage and bone damage, will enable the company to expand its platform into the screening and preventative health sector where early interventions can prevent future pain, improve mobility and greatly reduce health care costs associated with progressive, degenerative joint disease“, says Cunningham Thomas.

 

About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.

Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.

         For more information, please contact:
         Rosemary Cunningham Thomas, CEO, Episurf Medical
         Tel: +46 (0) 70-7655892
         Tel: +44 (0) 7803-753603
         E-mail: rosemary@episurf.com